In fall 2024, xanomeline trospium chloride (XT) was approved by the U.S. Food and Drug Administration for the treatment of adults with schizophrenia. In an earlier post, we reviewed evidence that this ...
Big Health Inc, along with paid academic investigators, reports higher remission rates and lower anxiety symptom scores with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback